Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
Henry Schein Closes Merritt Buyout, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) is consistently trying to expand its Animal Health business.
CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3
by Zacks Equity Research
CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.
Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders
by Zacks Equity Research
Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
by Zacks Equity Research
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business
by Zacks Equity Research
Express Scripts (ESRX) is consistently trying to expand its core PBM business.
Pacific Biosciences, Bluebee Team Up for De Novo Sequencing
by Zacks Equity Research
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.
QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite
by Zacks Equity Research
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Illumina (ILMN) Strong on Product Launches, Competition Rife
by Zacks Equity Research
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact
by Zacks Equity Research
Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
by Zacks Equity Research
Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.
4 Momentum Stocks That May Survive the Health Policy Mess
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable momentum picks.
VWR's New Kitting Center in Czech Republic to Boost EMEA Arm
by Zacks Equity Research
VWR's new strategically located 35,000 square foot facility in Skalice, Czech Republic looks to drive the company's business growth in the high-prospect EMEA region.
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
by Zacks Equity Research
Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.
Thermo Fisher Fundamentals Impressive Amid Tough Competition
by Zacks Equity Research
Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.
S&P 500 Nears 2,500: 5 Stock Picks for Big Profits
by Swarup Gupta
The index has nearly always gained in the one-year period immediately following this winning streak.
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines
8 Factors That Make Thermo Fisher a Valuable Pick Right Now
by Zacks Equity Research
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
Top Research Reports for Comcast, Thermo Fisher & China Life Insurance
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Thermo Fisher (TMO), and China Life Insurance (LFC).
Thermo Fisher Acquires Patheon, Boosts Laboratory Products
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.
Luminex Partners Sutter Health to Boost Molecular Testing
by Zacks Equity Research
The latest development is a significant addition to Luminex's (LMNX) molecular testing and diagnostic portfolio. The company has a broad product portfolio that comprises the advanced ARIES platform.
Thermo Fisher (TMO) Up 1.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.
Agilent (A) Sues Former Employees for Infringing IP Rights
by Zacks Equity Research
Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.